189 related articles for article (PubMed ID: 14693530)
1. In vitro and in vivo activities of a triterpenoid saponin extract (PX-6518) from the plant Maesa balansae against visceral leishmania species.
Maes L; Vanden Berghe D; Germonprez N; Quirijnen L; Cos P; De Kimpe N; Van Puyvelde L
Antimicrob Agents Chemother; 2004 Jan; 48(1):130-6. PubMed ID: 14693530
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo anti-leishmanial activity of triterpenoid saponins isolated from Maesa balansae and some chemical derivatives.
Germonprez N; Maes L; Van Puyvelde L; Van Tri M; Tuan DA; De Kimpe N
J Med Chem; 2005 Jan; 48(1):32-7. PubMed ID: 15633999
[TBL] [Abstract][Full Text] [Related]
3. Comparative activities of the triterpene saponin maesabalide III and liposomal amphotericin B (AmBisome) against Leishmania donovani in hamsters.
Maes L; Germonprez N; Quirijnen L; Van Puyvelde L; Cos P; Vanden Berghe D
Antimicrob Agents Chemother; 2004 Jun; 48(6):2056-60. PubMed ID: 15155199
[TBL] [Abstract][Full Text] [Related]
4. Antileishmanial activity and evaluation of the mechanism of action of strychnobiflavone flavonoid isolated from Strychnos pseudoquina against Leishmania infantum.
Lage PS; Chávez-Fumagalli MA; Mesquita JT; Mata LM; Fernandes SO; Cardoso VN; Soto M; Tavares CA; Leite JP; Tempone AG; Coelho EA
Parasitol Res; 2015 Dec; 114(12):4625-35. PubMed ID: 26346453
[TBL] [Abstract][Full Text] [Related]
5. An effective in vitro and in vivo antileishmanial activity and mechanism of action of 8-hydroxyquinoline against Leishmania species causing visceral and tegumentary leishmaniasis.
Costa Duarte M; dos Reis Lage LM; Lage DP; Mesquita JT; Salles BC; Lavorato SN; Menezes-Souza D; Roatt BM; Alves RJ; Tavares CA; Tempone AG; Coelho EA
Vet Parasitol; 2016 Feb; 217():81-8. PubMed ID: 26827866
[TBL] [Abstract][Full Text] [Related]
6. In vitro antileishmanial activity of leaf and stem extracts of seven Brazilian plant species.
de Paula RC; da Silva SM; Faria KF; Frézard F; Moreira CPS; Foubert K; Lopes JCD; Campana PRV; Rocha MP; Silva AF; Silva CG; Pieters L; Almeida VL
J Ethnopharmacol; 2019 Mar; 232():155-164. PubMed ID: 30580025
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo prophylactic and curative activity of the triterpene saponin PX-6518 against cutaneous Leishmania species.
Inocêncio da Luz RA; Vermeersch M; Deschacht M; Hendrickx S; Van Assche T; Cos P; Maes L
J Antimicrob Chemother; 2011 Feb; 66(2):350-3. PubMed ID: 21131319
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the antileishmanial potency, toxicity and phytochemical constituents of methanol bark extract of Sterculia villosa.
Das A; Das MC; Das N; Bhattacharjee S
Pharm Biol; 2017 Dec; 55(1):998-1009. PubMed ID: 28173714
[TBL] [Abstract][Full Text] [Related]
9. Ivermectin presents effective and selective antileishmanial activity in vitro and in vivo against Leishmania infantum and is therapeutic against visceral leishmaniasis.
Reis TAR; Oliveira-da-Silva JA; Tavares GSV; Mendonça DVC; Freitas CS; Costa RR; Lage DP; Martins VT; Machado AS; Ramos FF; Silva AM; Ludolf F; Antinarelli LMR; Brito RCF; Chávez-Fumagalli MA; Humbert MV; Roatt BM; Coimbra ES; Coelho EAF
Exp Parasitol; 2021 Feb; 221():108059. PubMed ID: 33338468
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of lapachol on treatment of cutaneous and visceral leishmaniasis.
Araújo IAC; de Paula RC; Alves CL; Faria KF; Oliveira MM; Mendes GG; Dias EMFA; Ribeiro RR; Oliveira AB; Silva SMD
Exp Parasitol; 2019 Apr; 199():67-73. PubMed ID: 30797783
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the Potential of Ursolic Acid as Bioproduct for Cutaneous and Visceral Leishmaniasis.
Bilbao-Ramos P; Serrano DR; Ruiz Saldaña HK; Torrado JJ; Bolás-Fernández F; Dea-Ayuela MA
Molecules; 2020 Mar; 25(6):. PubMed ID: 32204358
[TBL] [Abstract][Full Text] [Related]
12. LC-MS analysis of 13,28-epoxy-oleanane saponins in Maesa spp. extracts with antileishmanial activity.
Foubert K; Vermeersch M; Theunis M; Apers S; Cos P; Claeys M; Van Puyvelde L; Pieters L; Maes L
Phytochem Anal; 2009; 20(2):159-67. PubMed ID: 19219852
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis.
Soyer TG; Mendonça DVC; Tavares GSV; Lage DP; Dias DS; Ribeiro PAF; Perin L; Ludolf F; Coelho VTS; Ferreira ACG; Neves PHAS; Matos GF; Chávez-Fumagalli MA; Coimbra ES; Pereira GR; Coelho EAF; Antinarelli LMR
Exp Parasitol; 2019 Apr; 199():30-37. PubMed ID: 30817917
[TBL] [Abstract][Full Text] [Related]
14. In vivo antileishmanial activity and histopathological evaluation in Leishmania infantum infected hamsters after treatment with a furoxan derivative.
de Almeida L; Passalacqua TG; Dutra LA; Fonseca JNVD; Nascimento RFQ; Imamura KB; de Andrade CR; Dos Santos JL; Graminha MAS
Biomed Pharmacother; 2017 Nov; 95():536-547. PubMed ID: 28866421
[TBL] [Abstract][Full Text] [Related]
15. Digitoxigenin presents an effective and selective antileishmanial action against Leishmania infantum and is a potential therapeutic agent for visceral leishmaniasis.
Freitas CS; Oliveira-da-Silva JA; Lage DP; Costa RR; Mendonça DVC; Martins VT; Reis TAR; Antinarelli LMR; Machado AS; Tavares GSV; Ramos FF; Coelho VTS; Brito RCF; Ludolf F; Chávez-Fumagalli MA; Roatt BM; Ramos GS; Munkert J; Ottoni FM; Campana PRV; Humbert MV; Coimbra ES; Braga FC; Pádua RM; Coelho EAF
Parasitol Res; 2021 Jan; 120(1):321-335. PubMed ID: 33191446
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of liposomal buparvaquone in an experimental hamster model of Leishmania (L.) infantum chagasi.
Reimão JQ; Colombo FA; Pereira-Chioccola VL; Tempone AG
Exp Parasitol; 2012 Mar; 130(3):195-9. PubMed ID: 22281156
[TBL] [Abstract][Full Text] [Related]
17. Leishmanicidal and cytotoxic activities of Nigella sativa and its active principle, thymoquinone.
Mahmoudvand H; Tavakoli R; Sharififar F; Minaie K; Ezatpour B; Jahanbakhsh S; Sharifi I
Pharm Biol; 2015 Jul; 53(7):1052-7. PubMed ID: 25471014
[TBL] [Abstract][Full Text] [Related]
18. Antileishmanial efficacy and tolerability of combined treatment with non-ionic surfactant vesicle formulations of sodium stibogluconate and paromomycin in dogs.
Miret JA; Moreno J; Nieto J; Carter KC; Mullen AB; Ambros L; Rodríguez C; San Andrés MI; González F
Exp Parasitol; 2021 Jan; 220():108033. PubMed ID: 33166530
[TBL] [Abstract][Full Text] [Related]
19. Histamine H1-receptor antagonists against Leishmania (L.) infantum: an in vitro and in vivo evaluation using phosphatidylserine-liposomes.
Pinto EG; da Costa-Silva TA; Tempone AG
Acta Trop; 2014 Sep; 137():206-10. PubMed ID: 24905294
[TBL] [Abstract][Full Text] [Related]
20. Novel arylimidamides for treatment of visceral leishmaniasis.
Wang MZ; Zhu X; Srivastava A; Liu Q; Sweat JM; Pandharkar T; Stephens CE; Riccio E; Parman T; Munde M; Mandal S; Madhubala R; Tidwell RR; Wilson WD; Boykin DW; Hall JE; Kyle DE; Werbovetz KA
Antimicrob Agents Chemother; 2010 Jun; 54(6):2507-16. PubMed ID: 20368397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
